Shopping Cart 0
Cart Subtotal
USD 0

Europe Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 2700

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 4300

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 5800

Details

Europe biosimilars market was valued at USD 5,847.6 million in 2020 and will grow by 23.1% annually over 2020-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Highlighted with 37 tables and 57 figures, this 121-page report Europe Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Europe biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.

Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Recombinant Non-glycosylated Biosimilars

o Insulin

o Recombinant Human Growth Hormone (rHGH)

o Granulocyte Colony Stimulating Factor

o Interferon

Recombinant Glycosylated Biosimilars

o Monoclonal Antibodies (mAb)

o Erythropoietin (EPO)

o Follicle Stimulating Hormone

Recombinant Peptides and Others

o Tumor Necrosis Factor (TNF)-Inhibitor

o Parathyroid Hormone

o Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Cancer

Autoimmune Disease

Blood Disorder

Diabetes

Growth Hormone Deficiency

Infectious Diseases

Other Indications

Based on Manufacturing, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Contract Manufacturing

Inhouse Manufacturing

Based on End User, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Hospitals and Clinics

Research Institutes

Other End Users

Geographically, the following national/local markets are fully investigated:

Germany

UK

France

Spain

Italy

Russia

Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

For each key country, detailed analysis and data for annual revenue (USD mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Table Of Content

Scope

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 13

1.2.6 Market Size/Share Estimation 14

1.2.7 Research Limitations 15

1.3 Executive Summary 16

2 Market Overview and Dynamics 19

2.1 Market Size and Forecast 19

2.1.1 Impact of COVID-19 on World Economy 22

2.1.2 Impact of COVID-19 on the Market 25

2.2 Major Growth Drivers 27

2.3 Market Restraints and Challenges 32

2.4 Emerging Opportunities and Market Trends 35

2.5 Porter's Fiver Forces Analysis 39

3 Segmentation of Europe Market by Product Type 43

3.1 Market Overview by Product Type 43

3.2 Recombinant Non-glycosylated Biosimilars 45

3.2.1 Insulin 47

3.2.2 Recombinant Human Growth Hormone (rHGH) 48

3.2.3 Granulocyte Colony Stimulating Factor 49

3.2.4 Interferon 50

3.3 Recombinant Glycosylated Biosimilars 51

3.3.1 Monoclonal Antibodies (mAb) 52

3.3.2 Erythropoietin (EPO) 53

3.3.3 Follicle Stimulating Hormone 54

3.4 Recombinant Peptides and Others 55

3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 56

3.4.2 Parathyroid Hormone 57

3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 58

4 Segmentation of Europe Market by Indication 59

4.1 Market Overview by Indication 59

4.2 Cancer 61

4.3 Autoimmune Disease 62

4.4 Blood Disorder 63

4.5 Diabetes 64

4.6 Growth Hormone Deficiency 65

4.7 Infectious Diseases 66

4.8 Other Indications 67

5 Segmentation of Europe Market by Manufacturing 68

5.1 Market Overview by Manufacturing 68

5.2 Contract Manufacturing 70

5.3 Inhouse Manufacturing 71

6 Segmentation of Europe Market by End User 72

6.1 Market Overview by End User 72

6.2 Hospitals and Clinics 74

6.3 Research Institutes 75

6.4 Other End Users 76

7 European Market 2019-2030 by Country 77

7.1 Overview of European Market 77

7.2 Germany 82

7.3 U.K. 85

7.4 France 88

7.5 Spain 90

7.6 Italy 92

7.7 Russia 94

7.8 Rest of European Market 96

8 Competitive Landscape 98

8.1 Overview of Key Vendors 98

8.2 New Product Launch, Partnership, Investment, and M&A 102

8.3 Company Profiles 103

AMEGA Biotech S.A. 103

Apotex Inc. 105

Biocon Ltd 106

Biogen Inc. 107

Boehringer Ingelheim 108

Celltrion, Inc. 109

Dr. Reddy's Laboratories Ltd. 110

Eli Lilly and Company 111

Intas Pharmaceuticals Ltd. 112

LG Chem, Ltd. 113

Merck and Co. Inc. 114

Mylan N.V. 115

Pfizer Inc. 116

Samsung Biologics Co., Ltd. 117

Sandoz International GmbH 118

STADA Arzneimittel AG 119

Teva Pharmaceutical Industries Ltd. 120

RELATED REPORTS 121


List Of Figure

List of Figures:

Figure 1. Research Method Flow Chart 11

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14

Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16

Figure 4. Europe Biosimilars Market, 2019-2030, USD mn 19

Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 20

Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 20

Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 21

Figure 8. Impact of COVID-19 on Business 25

Figure 9. Primary Drivers and Impact Factors of Europe Biosimilars Market 27

Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30

Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 30

Figure 12. Primary Restraints and Impact Factors of Europe Biosimilars Market 32

Figure 13. Investment Opportunity Analysis 36

Figure 14. Porter's Fiver Forces Analysis of Europe Biosimilars Market 39

Figure 15. Breakdown of Europe Biosimilars Market by Product Type, 2019-2030, % of Revenue 44

Figure 16. Europe Addressable Market Cap in 2021-2030 by Product Type, Value (USD mn) and Share (%) 44

Figure 17. Europe Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, USD mn 45

Figure 18. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, USD mn 47

Figure 19. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, USD mn 48

Figure 20. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, USD mn 49

Figure 21. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, USD mn 50

Figure 22. Europe Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, USD mn 51

Figure 23. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, USD mn 52

Figure 24. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, USD mn 53

Figure 25. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, USD mn 54

Figure 26. Europe Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, USD mn 55

Figure 27. Europe Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, USD mn 56

Figure 28. Europe Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, USD mn 57

Figure 29. Europe Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, USD mn 58

Figure 30. Breakdown of Europe Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 60

Figure 31. Europe Addressable Market Cap in 2021-2030 by Indication, Value (USD mn) and Share (%) 60

Figure 32. Europe Biosimilars Market by Indication: Cancer, 2019-2030, USD mn 61

Figure 33. Europe Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, USD mn 62

Figure 34. Europe Biosimilars Market by Indication: Blood Disorder, 2019-2030, USD mn 63

Figure 35. Europe Biosimilars Market by Indication: Diabetes, 2019-2030, USD mn 64

Figure 36. Europe Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, USD mn 65

Figure 37. Europe Biosimilars Market by Indication: Infectious Diseases, 2019-2030, USD mn 66

Figure 38. Europe Biosimilars Market by Indication: Other Indications, 2019-2030, USD mn 67

Figure 39. Breakdown of Europe Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 69

Figure 40. Europe Addressable Market Cap in 2021-2030 by Manufacturing, Value (USD mn) and Share (%) 69

Figure 41. Europe Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, USD mn 70

Figure 42. Europe Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, USD mn 71

Figure 43. Breakdown of Europe Biosimilars Market by End User, 2019-2030, % of Revenue 73

Figure 44. Europe Addressable Market Cap in 2021-2030 by End User, Value (USD mn) and Share (%) 73

Figure 45. Europe Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, USD mn 74

Figure 46. Europe Biosimilars Market by End User: Research Institutes, 2019-2030, USD mn 75

Figure 47. Europe Biosimilars Market by End User: Other End Users, 2019-2030, USD mn 76

Figure 48. Breakdown of European Biosimilars Market by Country, 2019 and 2030, % of Revenue 78

Figure 49. Contribution to Europe 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 79

Figure 50. Biosimilars Market in Germany, 2019-2030, USD mn 82

Figure 51. Biosimilars Market in U.K., 2019-2030, USD mn 85

Figure 52. Biosimilars Market in France, 2019-2030, USD mn 88

Figure 53. Biosimilars Market in Spain, 2019-2030, USD mn 90

Figure 54. Biosimilars Market in Italy, 2019-2030, USD mn 92

Figure 55. Biosimilars Market in Russia, 2019-2030, USD mn 94

Figure 56. Biosimilars Market in Rest of Europe, 2019-2030, USD mn 96

Figure 57. Growth Stage of Europe Biosimilars Industry over the Forecast Period 98


List Of Table

List of Tables:

Table 1. Snapshot of Europe Biosimilars Market in Balanced Perspective, 2019-2030 17

Table 2. Growth Rate of World GDP, 2020-2022 23

Table 3. World Health Spending by Region, USD bn, 2013-2020 31

Table 4. Main Product Trends and Market Opportunities in Europe Biosimilars Market 35

Table 5. Europe Biosimilars Market by Product Type, 2019-2030, USD mn 43

Table 6. Europe Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, USD mn 46

Table 7. Europe Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, USD mn 51

Table 8. Europe Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, USD mn 55

Table 9. Europe Biosimilars Market by Indication, 2019-2030, USD mn 59

Table 10. Europe Biosimilars Market by Manufacturing, 2019-2030, USD mn 68

Table 11. Europe Biosimilars Market by End User, 2019-2030, USD mn 72

Table 12. Europe Biosimilars Market by Country, 2019-2030, USD mn 79

Table 13. Approved Biosimilars in Europe 80

Table 14. Germany Biosimilars Market by Product Type, 2019-2030, USD mn 83

Table 15. Germany Biosimilars Market by Indication, 2019-2030, USD mn 83

Table 16. Germany Biosimilars Market by End User, 2019-2030, USD mn 83

Table 17. U.K. Biosimilars Market by Product Type, 2019-2030, USD mn 87

Table 18. U.K. Biosimilars Market by Indication, 2019-2030, USD mn 87

Table 19. U.K. Biosimilars Market by End User, 2019-2030, USD mn 87

Table 20. France Biosimilars Market by Product Type, 2019-2030, USD mn 89

Table 21. France Biosimilars Market by Indication, 2019-2030, USD mn 89

Table 22. France Biosimilars Market by End User, 2019-2030, USD mn 89

Table 23. Spain Biosimilars Market by Product Type, 2019-2030, USD mn 91

Table 24. Spain Biosimilars Market by Indication, 2019-2030, USD mn 91

Table 25. Spain Biosimilars Market by End User, 2019-2030, USD mn 91

Table 26. Italy Biosimilars Market by Product Type, 2019-2030, USD mn 93

Table 27. Italy Biosimilars Market by Indication, 2019-2030, USD mn 93

Table 28. Italy Biosimilars Market by End User, 2019-2030, USD mn 93

Table 29. Russia Biosimilars Market by Product Type, 2019-2030, USD mn 95

Table 30. Russia Biosimilars Market by Indication, 2019-2030, USD mn 95

Table 31. Russia Biosimilars Market by End User, 2019-2030, USD mn 95

Table 32. Biosimilars Market in Rest of Europe by Country, 2019-2030, USD mn 97

Table 33. Breakdown of World Market by Key Vendor, 2020, % 100

Table 34. AMEGA Biotech S.A.: Company Snapshot 103

Table 35. AMEGA Biotech S.A.: Business Segmentation 103

Table 36. AMEGA Biotech S.A.: Product Portfolio 104

Table 37. AMEGA Biotech S.A.: Revenue, 2018-2020, USD mn 104

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Company Profile

Company Profile Title

Europe biosimilars market was valued at USD 5,847.6 million in 2020 and will grow by 23.1% annually over 2020-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Highlighted with 37 tables and 57 figures, this 121-page report Europe Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Europe biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.

Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Recombinant Non-glycosylated Biosimilars

o Insulin

o Recombinant Human Growth Hormone (rHGH)

o Granulocyte Colony Stimulating Factor

o Interferon

Recombinant Glycosylated Biosimilars

o Monoclonal Antibodies (mAb)

o Erythropoietin (EPO)

o Follicle Stimulating Hormone

Recombinant Peptides and Others

o Tumor Necrosis Factor (TNF)-Inhibitor

o Parathyroid Hormone

o Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Cancer

Autoimmune Disease

Blood Disorder

Diabetes

Growth Hormone Deficiency

Infectious Diseases

Other Indications

Based on Manufacturing, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Contract Manufacturing

Inhouse Manufacturing

Based on End User, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Hospitals and Clinics

Research Institutes

Other End Users

Geographically, the following national/local markets are fully investigated:

Germany

UK

France

Spain

Italy

Russia

Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

For each key country, detailed analysis and data for annual revenue (USD mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Scope

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 13

1.2.6 Market Size/Share Estimation 14

1.2.7 Research Limitations 15

1.3 Executive Summary 16

2 Market Overview and Dynamics 19

2.1 Market Size and Forecast 19

2.1.1 Impact of COVID-19 on World Economy 22

2.1.2 Impact of COVID-19 on the Market 25

2.2 Major Growth Drivers 27

2.3 Market Restraints and Challenges 32

2.4 Emerging Opportunities and Market Trends 35

2.5 Porter's Fiver Forces Analysis 39

3 Segmentation of Europe Market by Product Type 43

3.1 Market Overview by Product Type 43

3.2 Recombinant Non-glycosylated Biosimilars 45

3.2.1 Insulin 47

3.2.2 Recombinant Human Growth Hormone (rHGH) 48

3.2.3 Granulocyte Colony Stimulating Factor 49

3.2.4 Interferon 50

3.3 Recombinant Glycosylated Biosimilars 51

3.3.1 Monoclonal Antibodies (mAb) 52

3.3.2 Erythropoietin (EPO) 53

3.3.3 Follicle Stimulating Hormone 54

3.4 Recombinant Peptides and Others 55

3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 56

3.4.2 Parathyroid Hormone 57

3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 58

4 Segmentation of Europe Market by Indication 59

4.1 Market Overview by Indication 59

4.2 Cancer 61

4.3 Autoimmune Disease 62

4.4 Blood Disorder 63

4.5 Diabetes 64

4.6 Growth Hormone Deficiency 65

4.7 Infectious Diseases 66

4.8 Other Indications 67

5 Segmentation of Europe Market by Manufacturing 68

5.1 Market Overview by Manufacturing 68

5.2 Contract Manufacturing 70

5.3 Inhouse Manufacturing 71

6 Segmentation of Europe Market by End User 72

6.1 Market Overview by End User 72

6.2 Hospitals and Clinics 74

6.3 Research Institutes 75

6.4 Other End Users 76

7 European Market 2019-2030 by Country 77

7.1 Overview of European Market 77

7.2 Germany 82

7.3 U.K. 85

7.4 France 88

7.5 Spain 90

7.6 Italy 92

7.7 Russia 94

7.8 Rest of European Market 96

8 Competitive Landscape 98

8.1 Overview of Key Vendors 98

8.2 New Product Launch, Partnership, Investment, and M&A 102

8.3 Company Profiles 103

AMEGA Biotech S.A. 103

Apotex Inc. 105

Biocon Ltd 106

Biogen Inc. 107

Boehringer Ingelheim 108

Celltrion, Inc. 109

Dr. Reddy's Laboratories Ltd. 110

Eli Lilly and Company 111

Intas Pharmaceuticals Ltd. 112

LG Chem, Ltd. 113

Merck and Co. Inc. 114

Mylan N.V. 115

Pfizer Inc. 116

Samsung Biologics Co., Ltd. 117

Sandoz International GmbH 118

STADA Arzneimittel AG 119

Teva Pharmaceutical Industries Ltd. 120

RELATED REPORTS 121


List Of Figure

List of Figures:

Figure 1. Research Method Flow Chart 11

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14

Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16

Figure 4. Europe Biosimilars Market, 2019-2030, USD mn 19

Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 20

Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 20

Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 21

Figure 8. Impact of COVID-19 on Business 25

Figure 9. Primary Drivers and Impact Factors of Europe Biosimilars Market 27

Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30

Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 30

Figure 12. Primary Restraints and Impact Factors of Europe Biosimilars Market 32

Figure 13. Investment Opportunity Analysis 36

Figure 14. Porter's Fiver Forces Analysis of Europe Biosimilars Market 39

Figure 15. Breakdown of Europe Biosimilars Market by Product Type, 2019-2030, % of Revenue 44

Figure 16. Europe Addressable Market Cap in 2021-2030 by Product Type, Value (USD mn) and Share (%) 44

Figure 17. Europe Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, USD mn 45

Figure 18. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, USD mn 47

Figure 19. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, USD mn 48

Figure 20. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, USD mn 49

Figure 21. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, USD mn 50

Figure 22. Europe Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, USD mn 51

Figure 23. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, USD mn 52

Figure 24. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, USD mn 53

Figure 25. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, USD mn 54

Figure 26. Europe Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, USD mn 55

Figure 27. Europe Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, USD mn 56

Figure 28. Europe Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, USD mn 57

Figure 29. Europe Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, USD mn 58

Figure 30. Breakdown of Europe Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 60

Figure 31. Europe Addressable Market Cap in 2021-2030 by Indication, Value (USD mn) and Share (%) 60

Figure 32. Europe Biosimilars Market by Indication: Cancer, 2019-2030, USD mn 61

Figure 33. Europe Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, USD mn 62

Figure 34. Europe Biosimilars Market by Indication: Blood Disorder, 2019-2030, USD mn 63

Figure 35. Europe Biosimilars Market by Indication: Diabetes, 2019-2030, USD mn 64

Figure 36. Europe Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, USD mn 65

Figure 37. Europe Biosimilars Market by Indication: Infectious Diseases, 2019-2030, USD mn 66

Figure 38. Europe Biosimilars Market by Indication: Other Indications, 2019-2030, USD mn 67

Figure 39. Breakdown of Europe Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 69

Figure 40. Europe Addressable Market Cap in 2021-2030 by Manufacturing, Value (USD mn) and Share (%) 69

Figure 41. Europe Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, USD mn 70

Figure 42. Europe Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, USD mn 71

Figure 43. Breakdown of Europe Biosimilars Market by End User, 2019-2030, % of Revenue 73

Figure 44. Europe Addressable Market Cap in 2021-2030 by End User, Value (USD mn) and Share (%) 73

Figure 45. Europe Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, USD mn 74

Figure 46. Europe Biosimilars Market by End User: Research Institutes, 2019-2030, USD mn 75

Figure 47. Europe Biosimilars Market by End User: Other End Users, 2019-2030, USD mn 76

Figure 48. Breakdown of European Biosimilars Market by Country, 2019 and 2030, % of Revenue 78

Figure 49. Contribution to Europe 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 79

Figure 50. Biosimilars Market in Germany, 2019-2030, USD mn 82

Figure 51. Biosimilars Market in U.K., 2019-2030, USD mn 85

Figure 52. Biosimilars Market in France, 2019-2030, USD mn 88

Figure 53. Biosimilars Market in Spain, 2019-2030, USD mn 90

Figure 54. Biosimilars Market in Italy, 2019-2030, USD mn 92

Figure 55. Biosimilars Market in Russia, 2019-2030, USD mn 94

Figure 56. Biosimilars Market in Rest of Europe, 2019-2030, USD mn 96

Figure 57. Growth Stage of Europe Biosimilars Industry over the Forecast Period 98


List Of Table

List of Tables:

Table 1. Snapshot of Europe Biosimilars Market in Balanced Perspective, 2019-2030 17

Table 2. Growth Rate of World GDP, 2020-2022 23

Table 3. World Health Spending by Region, USD bn, 2013-2020 31

Table 4. Main Product Trends and Market Opportunities in Europe Biosimilars Market 35

Table 5. Europe Biosimilars Market by Product Type, 2019-2030, USD mn 43

Table 6. Europe Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, USD mn 46

Table 7. Europe Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, USD mn 51

Table 8. Europe Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, USD mn 55

Table 9. Europe Biosimilars Market by Indication, 2019-2030, USD mn 59

Table 10. Europe Biosimilars Market by Manufacturing, 2019-2030, USD mn 68

Table 11. Europe Biosimilars Market by End User, 2019-2030, USD mn 72

Table 12. Europe Biosimilars Market by Country, 2019-2030, USD mn 79

Table 13. Approved Biosimilars in Europe 80

Table 14. Germany Biosimilars Market by Product Type, 2019-2030, USD mn 83

Table 15. Germany Biosimilars Market by Indication, 2019-2030, USD mn 83

Table 16. Germany Biosimilars Market by End User, 2019-2030, USD mn 83

Table 17. U.K. Biosimilars Market by Product Type, 2019-2030, USD mn 87

Table 18. U.K. Biosimilars Market by Indication, 2019-2030, USD mn 87

Table 19. U.K. Biosimilars Market by End User, 2019-2030, USD mn 87

Table 20. France Biosimilars Market by Product Type, 2019-2030, USD mn 89

Table 21. France Biosimilars Market by Indication, 2019-2030, USD mn 89

Table 22. France Biosimilars Market by End User, 2019-2030, USD mn 89

Table 23. Spain Biosimilars Market by Product Type, 2019-2030, USD mn 91

Table 24. Spain Biosimilars Market by Indication, 2019-2030, USD mn 91

Table 25. Spain Biosimilars Market by End User, 2019-2030, USD mn 91

Table 26. Italy Biosimilars Market by Product Type, 2019-2030, USD mn 93

Table 27. Italy Biosimilars Market by Indication, 2019-2030, USD mn 93

Table 28. Italy Biosimilars Market by End User, 2019-2030, USD mn 93

Table 29. Russia Biosimilars Market by Product Type, 2019-2030, USD mn 95

Table 30. Russia Biosimilars Market by Indication, 2019-2030, USD mn 95

Table 31. Russia Biosimilars Market by End User, 2019-2030, USD mn 95

Table 32. Biosimilars Market in Rest of Europe by Country, 2019-2030, USD mn 97

Table 33. Breakdown of World Market by Key Vendor, 2020, % 100

Table 34. AMEGA Biotech S.A.: Company Snapshot 103

Table 35. AMEGA Biotech S.A.: Business Segmentation 103

Table 36. AMEGA Biotech S.A.: Product Portfolio 104

Table 37. AMEGA Biotech S.A.: Revenue, 2018-2020, USD mn 104

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)